NGM Biopharmaceuticals Email Format
Biotechnology ResearchCalifornia, United States51-200 Employees
NGM Biopharmaceuticals is a biotechnology research company headquartered in South San Francisco, California, focused on discovering and developing novel medicines for diseases that disrupt health and lives. The company employs 51-200 people. NGM Bio pursues a portfolio that includes NGM707 in advanced solid tumors and aldafermin and NGM120, with an emphasis on rare conditions with significant unmet need. In 2024 the company completed a financing round and launched a clinical trial of aldafermin for PSC, along with other program developments. In February 2025, NGM Biopharmaceuticals appointed Wendy Yeh, M.D., as Chief Medical Officer, following her prior role as Senior Vice President of Clinical Development at Vir Biotechnology.